Get the Stockscreener App
24.79
0.76%
-0.19
After Hours:
24.80
0.01
+0.04%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $24.79, with a volume of 30.71M.
It is down -0.76% in the last 24 hours and up +5.53% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$24.98
Open:
$24.88
24h Volume:
30.71M
Relative Volume:
0.77
Market Cap:
$140.94B
Revenue:
$63.83B
Net Income/Loss:
$10.77B
P/E Ratio:
13.19
EPS:
1.88
Net Cash Flow:
$12.44B
1W Performance:
-1.12%
1M Performance:
+5.53%
6M Performance:
-5.56%
1Y Performance:
-12.40%
1-Day Range:
$24.72
$25.12
1-Week Range:
$24.51
$25.12
52-Week Range:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.79 | 142.03B | 63.83B | 10.77B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
737.83 | 659.07B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.00 | 428.83B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
211.86 | 374.37B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
128.23 | 245.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.18 | 213.51B | 63.43B | 16.42B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer CEO is latest to say Trump should get Nobel Peace Prize – for something much of MAGA hates - AOL.com
Cassidy, Pfizer CEO: Trump worthy of Nobel prize for COVID vaccine - AOL.com
Trump "worthy of the Nobel Peace Prize" for COVID vaccines, Pfizer CEO says - Axios
Pfizer, Moderna, Novavax respond to Trump’s criticism of COVID shot success - Seeking Alpha
Pfizer, Moderna defend COVID vaccine effectiveness after Trump remarks - Reuters
Pfizer collaboration with Olema may spark future bidding waranalyst (OLMA:NASDAQ) - Seeking Alpha
Prostate Cancer Pipeline Analysi, 2025 by DelveInsight | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Phar - Barchart.com
Pfizer defends COVID-19 vaccine effectiveness after Trump remarks - Reuters
Responding to Trump, Pfizer CEO Bourla stands by Covid-19 vaccine data - Endpoints News
Pfizer responds to Trump’s call for Covid-19 vaccine data, says Operation Warp Speed deserves Nobel Peace Prize - news8000.com
Pfizer (PFE) Partners With Olema For New Metastatic Breast Cancer Study - simplywall.st
Pfizer Reaffirms Transparency Commitment On COVID-19 Vaccine Data - Nasdaq
PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight - GlobeNewswire Inc.
Pfizer Defends Covid Shot, Says Trump Deserves Nobel Prize - Yahoo Finance
Pfizer defends Covid-19 vaccine transparency in response to Trump - The Edge Malaysia
Pfizer Defends Covid Vaccine Transparency in Response to Trump - Bloomberg.com
Pfizer : Responds to Success of Operation Warp Speed and Reaffirms Transparency of COVID Vaccine Data - MarketScreener
Pfizer says it will soon share new data on latest vaccine strain which FDA approved - MarketScreener
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Pfizer (PFE) Volatility and Risk Allocation: Navigating a Shifting Pharmaceutical Landscape - AInvest
Pfizer's Strategic Reinvention: Execution Discipline and Risk Allocation Reshape Valuation Narrative - AInvest
Pfizer's Strategic Volatility: Tactical Entry Points and Rule-Based Trading in a Biotech Recovery - AInvest
Pfizer's Strategic Volatility: Decoding Recent Share Price Swings and Tactical Entry Points - AInvest
Pfizer's Surging Momentum: A Catalyst for Large-Cap Biotech Growth - AInvest
$33M Pfizer Antitrust Deal OK'd, First MDL Trial Date Set - Law360
Pfizer's Golden Cross and Pipeline Progress: A Dividend-Driven Turnaround or a Value-Trap Mirage? - AInvest
Pfizer's Pipeline Monetization and 7% Yield: A Dual-Engine Opportunity in a Re-Rating Pharma Landscape - AInvest
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer Defends Transparency On COVID-19 Vaccine Data, Says Trump’s ‘Operation Warp Speed’ Effort Deserves Nobel Peace Prize - Stocktwits
Backtesting results for Pfizer Inc. trading strategiesTrade Risk Report & Safe Entry Trade Signal Reports - Newser
Can Pfizer Inc. recover in the next quarterTrade Signal Summary & Daily Chart Pattern Signal Reports - Newser
Olema stock jumps after new clinical trial collaboration with Pfizer - Investing.com
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer: Pipeline Monetization Shows Great PromiseRich Yields Pending Re-Rating (NYSE:PFE) - Seeking Alpha
Is Pfizer Stock Underperforming the Nasdaq? - Yahoo Finance
Olema Pharmaceuticals, Pfizer Collaborate for Clinical Trial of Breast Cancer Treatment - MarketScreener
Olema Pharmaceuticals Partners with Pfizer for New Trial - TipRanks
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer - The Manila Times
Pfizer, Moderna in focus as Trump demands answers on COVID success - Seeking Alpha
Olema Oncology Announces New Clinical Trial Agreement with - GlobeNewswire
Novel Breast Cancer Treatment: Olema and Pfizer Join Forces on Promising Drug Combination Study - Stock Titan
Is Pfizer Inc. reversing from oversold territoryJuly 2025 Action & Smart Allocation Stock Tips - Newser
Pfizer (PFE) Valuation in Focus Following FDA Approval of Updated COVID-19 Vaccine - simplywall.st
Stock Analysis | Pfizer OutlookMixed Signals as Technicals Deter and Fundamentals Stay Strong - AInvest
Contract Pharma Talks with Bruno Sciamanna and Lillian Glennon of Pfizer CentreOne - Contract Pharma
Pfizer Inc. (PFE)’s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide - Yahoo Finance
Trump Demands Pfizer, Other Covid Drug Makers To… - inkl
Unit Dose Packaging Market Top Companies StudyPfizer Inc., - openPR.com
Is Pfizer Inc. trending in predictive chart modelsWeekly Profit Summary & Real-Time Buy Signal Notifications - Newser
Advanced analytics toolkit walkthrough for Pfizer Inc.Quarterly Market Summary & Expert Approved Momentum Ideas - Newser
How to read the order book for Pfizer Inc.July 2025 Weekly Recap & Weekly High Potential Alerts - Newser
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):